New first-line treatment option for metastatic kidney cancer
The results of the phase 3 CheckMate 9ER trial have provided a new first-line treatment option for patients with metastatic […]
» Read moreHome »
An immunotherapy drug called ‘avelumab’ has been shown to significantly improve survival in patients with the most common type of […] Inflammatory bowel diseases (IBD) such as Crohn’s disease and ulcerative colitis are caused by unrestrained inflammation of the gastrointestinal tract. […] Delays and cancelation of cancer treatments and other safety measures undertaken to minimize the risk of exposure to the coronavirus […] Scientists at Johns Hopkins Medicine and the University of Oxford say they have found a new way to kill some […] (HealthDay)—The risk for cancer is reduced among patients with multiple sclerosis (MS), according to a systematic review and meta-analysis published […] Bowel cancer is one of the most common cancers to be diagnosed in the UK. You should consider speaking to […] Dad-of-one Graham Wood, 36, has terminal brain cancer and when he was diagnosed in 2015, he was told he would […] Breast cancer rates among women globally are on the rise, but new research is uncovering trends related to age and […] A drug known as SP-2577 could help enable the body’s own immune system to attack ovarian cancer, according to a […]
Immunotherapy improves survival in advanced bladder cancer patients
Study reveals how cannabinoids may be useful to prevent colon cancer
COVID-19 pandemic halts cancer care and damages oncologists’ well-being
New way to target some rapidly dividing cancer cells, leaving healthy cells unharmed
Risk for cancer reduced for patients with multiple sclerosis
Bowel cancer warning: Does your poo sink or float? Hidden signs of a tumour in the toilet
Dad with terminal cancer fundraises for son diagnosed with life-limiting illness
Study finds global trends in women’s breast cancer show cause for concern
Study: The immune effects of seclidemstat in aggressive ovarian cancer striking young women
